Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
QAU145 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | QAU145 |
| 2 | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| QAU145 | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * Male and female (women must be post-menopausal or surgically sterile) subjects with cystic fibrosis ages 18 to 50. Exclusion Criteria: * Any presence of seasonal or non-seasonal allergies affecting the nose, nasal passages, throat or sinuses within 2 weeks prior to dosing. *...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | VRTX | 8 | PHASE3 | VX-121/TEZ/D-IVA |
| Sionna Therapeutics, Inc. | SION | 2 | PHASE2 | SION-719 |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| 4D Molecular Therapeutics, Inc. | FDMT | 1 | PHASE2 | 4D-710 |
| Arcturus Therapeutics Holdings, Inc. | ARCT | 1 | PHASE2 | ARCT-032 |
| Krystal Biotech, Inc. | KRYS | 1 | PHASE1 | KB407 |
| Illumina, Inc. | ILMN | 1 | - | Undisclosed |
QAU145 is an investigational small molecule being studied for the treatment of cystic fibrosis. It was evaluated in a Phase 2 clinical trial to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with the condition. The drug is not approved and remains in clinical development.
QAU145 is being developed by Novartis AG, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. The company sponsored the Phase 2 clinical trial of QAU145 in patients with cystic fibrosis.
QAU145 is in Phase 2 clinical development. A Phase 2 trial of the drug in patients with cystic fibrosis has been completed. QAU145 is an investigational drug and has not been approved by regulatory authorities.
QAU145 has been studied in one clinical trial, identified as NCT00506792. This was a Phase 2, randomized, double-blind, placebo-controlled study titled "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QAU145 in Patients With Cystic Fibrosis." The trial enrolled 9 participants in the United States and has been completed.
QAU145 is not FDA approved. It is an investigational small molecule that has completed a Phase 2 clinical trial in patients with cystic fibrosis. The drug is still in clinical development and has not been authorized for commercial use.